Results 71 to 80 of about 154,390 (283)
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Flexibilities under Trips: Implementation Gaps between Theory and Practice
Nordic Journal of Commercial Law, 2013 Agreement on Trade Related Aspects of Intellectual Property (hereinafter TRIPS) aimed at fostering innovation and developing a system based on innovation-oriented national economies.
Muhammad Zaheer Abbas, Shamreeza Riaz
doaj +2 more sources
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Features of legal protection of medical inventions: present and future
Patologìâ, 2019 The modern legal doctrine of intellectual property practically does not investigate the terms of legal protection of inventions in medical practice. Aim.
V. I. Teremetskyi +4 more
doaj +1 more source
Brief of Law Professors as Amicus Curiae in Support of Respondent [PDF]
, 2003 Inventors lacking assurance of a market, or even the right to practice patented inventions, face considerable risk. Those who qualify for patents, in return for disclosure, receive only the assistance of the courts in excluding others from economic ...
Field, Thomas G., Jr +3 more
core +1 more source
Strength through diversity: how cancers thrive when clones cooperate
Molecular Oncology, EarlyView.Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken +3 more
wiley +1 more source
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Korea, the Pharmaceutical Industry and Non-Commercial Use in the TRIPS Agreement [PDF]
In 2002, a number of associations requested the Korean Patent Office to issue a compulsory license for the manufacture of a drug under the Korean patent provision which permits the issue of compulsory licensing for public non-commercial use.
Shanker, Daya
core
No pills for poor people? Understanding the disembowelment of India’s patent regime [PDF]
, 2005 The recent amendment to the Patent Act, 1970 brings India into full compliance with its obligations under the TRIPs Agreement, in particular allowing for product patents in the area of pharmaceuticals and agrichemicals.
Rangnekar, Dwijen
core
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source